Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a Phase 2, randomized, doubleblind, placebo-controlled study

Authors
Category Primary study
JournalJournal of Clinical and Aesthetic Dermatology
Year 2023
This article has no abstract
Epistemonikos ID: abb99c19a05eee14e4ff95a2da10c6de666fd80a
First added on: Feb 15, 2025